OncoGenex Pharmaceuticals Inc (OGXI)

0.51
0.04 7.87
NASDAQ : Health Care
Prev Close 0.47
Open 0.46
Day Low/High 0.46 / 0.51
52 Wk Low/High 0.46 / 4.10
Volume 217.10K
Avg Volume 243.10K
Exchange NASDAQ
Shares Outstanding 30.01M
Market Cap 14.70M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

8 Breakout Stocks Under $10 to Trade for Big Profits

8 Breakout Stocks Under $10 to Trade for Big Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

4 Stocks Under $10 to Trade for Big Breakouts

4 Stocks Under $10 to Trade for Big Breakouts

These stocks trading for less than $10 a share are within range of triggering major breakout trades.

OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion Of Futility Analysis

OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion Of Futility Analysis

Data Safety Monitoring Board Recommends Continuation of Trial as Planned in Bladder Cancer Patients

OncoGenex Announces EMA Support For Phase 3 AFFINITY Trial Protocol Amendment

OncoGenex Announces EMA Support For Phase 3 AFFINITY Trial Protocol Amendment

Topline Results in Poor Prognosis Subpopulation Expected by End of Year

OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes

OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes

Data Presented at 2015 European Cancer Congress Includes Further Analysis from Borealis-1TM Trial of Apatorsen in Metastatic Bladder Cancer

OncoGenex Pharmaceuticals (OGXI) Is Today's Strong On High Volume Stock

OncoGenex Pharmaceuticals (OGXI) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified OncoGenex Pharmaceuticals (OGXI) as a strong on high relative volume candidate

OncoGenex Pharmaceuticals (OGXI) Weak On High Volume Today

OncoGenex Pharmaceuticals (OGXI) Weak On High Volume Today

Trade-Ideas LLC identified OncoGenex Pharmaceuticals (OGXI) as a weak on high relative volume candidate

OncoGenex Announces Custirsen Phase 3

OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion Of Final Futility Survival Analysis

Rigorous Criteria Met, Trial in NSCLC Patients Proceeds as Planned

FDA Agrees With OncoGenex' Phase 3 AFFINITY Protocol Amendment

FDA Agrees With OncoGenex' Phase 3 AFFINITY Protocol Amendment

Co-primary Survival Endpoint Included for a Prospectively-Defined Poor Prognosis Subpopulation

OncoGenex Announces Data From The Phase 3 SYNERGY Trial Showing A Survival Benefit With Custirsen In Patients With Poor Prognosis

OncoGenex Announces Data From The Phase 3 SYNERGY Trial Showing A Survival Benefit With Custirsen In Patients With Poor Prognosis

Significant reduction in risk of death observed in those patients with most common risk factors that drive poor outcomes in prostate cancer